Conflicts of interest None declared.
Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis
Article first published online: 24 OCT 2006
British Journal of Dermatology
Volume 155, Issue 6, pages 1256–1261, December 2006
How to Cite
Fölster-Holst, R., Müller, F., Schnopp, N., Abeck, D., Kreiselmaier, I., Lenz, T., Von Rüden, U., Schrezenmeir, J., Christophers, E. and Weichenthal, M. (2006), Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. British Journal of Dermatology, 155: 1256–1261. doi: 10.1111/j.1365-2133.2006.07558.x
- Issue published online: 24 OCT 2006
- Article first published online: 24 OCT 2006
- Accepted for publication 9 June 2006
- atopic dermatitis;
- paediatric dermatology;
- randomized controlled trial
Background A reduction of symptoms of atopic dermatitis (AD) in small infants by the administration of Lactobacillus rhamnosus has been reported in a few studies. One study with older children and adolescents failed to show any effect.
Objectives We conducted a prospective study to reassess the efficacy of orally administered L. rhamnosus strain GG (LGG) in infants with AD.
Methods In a randomized, double-blind, placebo-controlled study, 54 infants aged 1–55 months with moderate to severe AD were randomized to daily 10 × 109 colony-forming units of LGG or to placebo during an 8-week intervention phase. Emollients, class I–II topical corticosteroids and antihistamines were permitted.
Results The treatment with LGG was well tolerated. At the end of treatment there were no significant differences between the groups with respect to clinical symptoms (SCORAD, pruritus, sleep loss), the use of topical corticosteroids and antihistamines, immunological parameters, or health-related quality of life of the parents.
Conclusions Our results could not confirm LGG as an effective treatment of AD in infancy.